KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Fulgent Genetics (FLGT) over the last 11 years, with Q3 2025 value amounting to 18.26%.

  • Fulgent Genetics' EBIT Margin rose 55500.0% to 18.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 22.5%, marking a year-over-year increase of 527100.0%. This contributed to the annual value of 26.08% for FY2024, which is 415300.0% up from last year.
  • As of Q3 2025, Fulgent Genetics' EBIT Margin stood at 18.26%, which was up 55500.0% from 24.1% recorded in Q2 2025.
  • In the past 5 years, Fulgent Genetics' EBIT Margin ranged from a high of 74.26% in Q1 2021 and a low of 214.34% during Q4 2023
  • Over the past 5 years, Fulgent Genetics' median EBIT Margin value was 21.17% (recorded in 2024), while the average stood at 8.81%.
  • In the last 5 years, Fulgent Genetics' EBIT Margin plummeted by -1603500bps in 2023 and then soared by 1931700bps in 2024.
  • Fulgent Genetics' EBIT Margin (Quarter) stood at 59.94% in 2021, then tumbled by -190bps to 53.99% in 2022, then plummeted by -297bps to 214.34% in 2023, then skyrocketed by 90bps to 21.17% in 2024, then increased by 14bps to 18.26% in 2025.
  • Its EBIT Margin was 18.26% in Q3 2025, compared to 24.1% in Q2 2025 and 26.95% in Q1 2025.